HP537 / Hinova Pharma - LARVOL DELTA

Discovery of HP537, a potent and selective p300/CBP inhibitor for the treatment of hematologic malignancies (AACR 2024) - "A FIH study of HP537 in cancer patients is planned to start in 2024. HP537 structure will not be disclosed."

Late-breaking abstract • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Lymphoma • Multiple Myeloma • Non-Hodgkin’s Lymphoma • Oncology • BRD4 • CREBBP • EP300 • HAT1 • IRF4 • MYC

Haichuang Pharmaceutical Co., Ltd. voluntarily discloses the announcement that HP537 tablets have received the clinical trial application acceptance notice [Google translation] (Shanghai Securities News) - "...Haichuang Pharmaceutical Co., Ltd. (hereinafter referred to as the 'Company') received an 'Acceptance Notice' approved and issued by the State Food and Drug Administration. The company's independently developed HP537 tablets are used to treat hematological malignancies, including but not limited to Multiple myeloma (MM), non-Hodgkin's lymphoma (NHL), acute myeloid leukemia (AML), myelodysplastic syndromes (MDS). The clinical trial application was accepted."

New trial • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Lymphoma • Multiple Myeloma • Myelodysplastic Syndrome • Non-Hodgkin’s Lymphoma • Oncology